Document is current
Any future updates will be listed below
-
Authors
McPherson, Andrew https://orcid.org/0000-0002-5654-5101
Vázquez-García, Ignacio
Myers, Matthew A. https://orcid.org/0000-0002-9337-5180
Al-Rawi, Duaa H. https://orcid.org/0000-0002-9218-6513
Zatzman, Matthew https://orcid.org/0000-0001-5235-4116
Weiner, Adam C. https://orcid.org/0000-0002-5968-3606
Freeman, Samuel https://orcid.org/0000-0001-8285-0057
Mohibullah, Neeman
Satas, Gryte
Williams, Marc J. https://orcid.org/0000-0001-5524-4174
Ceglia, Nicholas
Norkūnaitė, Danguolė
Zhang, Allen W.
Li, Jun https://orcid.org/0000-0002-6836-2716
Lim, Jamie L. P.
Wu, Michelle https://orcid.org/0000-0001-6889-8345
Choi, Seongmin https://orcid.org/0000-0001-9722-1800
Havasov, Eliyahu
Grewal, Diljot
Shi, Hongyu
Kim, Minsoo
Schwarz, Roland F. https://orcid.org/0000-0001-9155-4268
Kaufmann, Tom
Dinh, Khanh Ngoc
Uhlitz, Florian
Tran, Julie
Wu, Yushi
Patel, Ruchi
Ramakrishnan, Satish
Kim, DooA
Clarke, Justin
Green, Hunter https://orcid.org/0009-0002-3944-6803
Ali, Emily https://orcid.org/0009-0004-9372-0679
DiBona, Melody https://orcid.org/0000-0002-8853-2604
Varice, Nancy https://orcid.org/0009-0008-5813-0808
Kundra, Ritika https://orcid.org/0000-0001-6723-2859
Broach, Vance
Gardner, Ginger J.
Roche, Kara Long
Sonoda, Yukio
Zivanovic, Oliver
Kim, Sarah H.
Grisham, Rachel N.
Liu, Ying L. https://orcid.org/0000-0001-5790-851X
Viale, Agnes
Rusk, Nicole https://orcid.org/0000-0003-2663-6288
Lakhman, Yulia https://orcid.org/0000-0003-3626-4502
Ellenson, Lora H.
Tavaré, Simon https://orcid.org/0000-0002-3716-4952
Aparicio, Samuel https://orcid.org/0000-0002-0487-9599
Chi, Dennis S.
Aghajanian, Carol
Abu-Rustum, Nadeem R.
Friedman, Claire F. https://orcid.org/0000-0003-2621-8553
Zamarin, Dmitriy
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Bakhoum, Samuel F. https://orcid.org/0000-0002-4779-8422
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 4 June 2025
First Online: 16 July 2025
Competing interests
: B.W. reports grant funding by Repare Therapeutics paid to the institution, outside the scope of this paper, and employment of a direct family member at AstraZeneca. C.A. reports grants from Clovis, Genentech, AbbVie and AstraZeneca, and personal fees from Tesaro, Eisai/Merck, Mersana Therapeutics, Roche/Genentech, Abbvie, AstraZeneca/Merck and Repare Therapeutics, outside the scope of this paper. C.A. also reports clinical-trial funding to the institution from Abbvie, AstraZeneca and Genentech/Roche; participation on a data safety monitoring board or advisory board at AstraZeneca and Merck; unpaid membership of the GOG Foundation board of directors and the NRG Oncology board of directors. C.F.F. reports research funding to the institution from Merck, AstraZeneca, Genentech/Roche, Bristol Myers Squibb and Daiichi; uncompensated membership of a scientific advisory board for Merck and Genentech; and is a consultant for OncLive, Aptitude Health, Bristol Myers Squibb and Seagen, all outside the scope of this paper. D.S.C. reports membership of the medical advisory board of Verthermia Acquio and Biom’up, is a paid speaker for AstraZeneca and holds stock of Doximity, Moderna and BioNTech. D.Z. reports institutional grants from Merck, Genentech, AstraZeneca, Plexxikon and Synthekine, and personal fees from AstraZeneca, Xencor, Memgen, Takeda, Astellas, Immunos, Tessa Therapeutics, Miltenyi and Calidi Biotherapeutics. D.Z. holds a patent on the use of oncolytic Newcastle disease virus for cancer therapy. N.R.A.-R. reports grants to the institution from Stryker/Novadaq and GRAIL, outside the scope of this paper. R.N.G. reports funding from GSK, Novartis, Mateon Therapeutics, Corcept, Regeneron, Clovis, Context Therapeutics, EMD Serono, MCM Education, OncLive, Aptitude Health and Prime Oncology, outside the scope of this paper. S.F.B. owns equity in, receives compensation from and serves as a consultant and on the scientific advisory board and board of directors of Volastra Therapeutics. He also serves on the scientific advisory board of Meliora Therapeutics. S.P.S. reports research funding from AstraZeneca and Bristol Myers Squibb, outside the scope of this paper. Y.L.L. reports research funding from AstraZeneca, GSK/Tesaro, Artios Pharma and Tesaro Therapeutics, outside the scope of this paper. Y.L. reports serving as a consultant for Calyx Clinical Trial Solutions, outside the scope of this paper. All the remaining authors declare no competing interests.
